ArticleClinical rheumatology2025
Clinical characteristics of Hispanic patients with anti-SAE dermatomyositis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesFive autoantibodies are considered specific for dermatomyositis (DM). Among them, anti-small ubiquitin-like modifier (SUMO) activating enzyme (SAE) antibodies are the most infrequent. Information on anti-SAE DM remains limited. We aimed to describe the clinical and serological features of Hispanic patients with anti-SAE DM.
methodsWe performed a cross-sectional study at the University Hospital "Dr. José Eleuterio González" in Monterrey, Mexico. The rheumatology laboratory database was searched for all autoimmune inflammatory myopathy immunoblot panels performed from February 2016 to December 2023. Patients with moderate positive or strong positive for anti-SAE, a DM diagnosis by a rheumatologist, and follow-up at our institution were included. Clinical and demographic information was then retrieved from medical records.
resultsA total of 1018 panels were evaluated. Anti-SAE was moderately positive in 4 (0.39%) cases and strongly positive in 10 (0.98%), of which 7 patients met the inclusion criteria. All patients presented skin involvement, including atypical manifestations such as hiker's feet, erythroderma, and panniculitis. Four patients had muscle involvement, of which 2 had elevated creatine kinase levels. Dysphagia was reported in 3 cases. Two patients had interstitial lung disease. No cases of malignancy were identified at follow-up.
conclusionsOur study highlights the clinical presentation of anti-SAE DM in Hispanic patients, emphasizing the prevalent cutaneous involvement and variable systemic manifestations. Recognizing these features can aid in earlier diagnosis and management. Key Points • Anti-SAE antibody-associated dermatomyositis is uncommon, with 1.4% of evaluated panels showing moderate to strong positivity. • All seven patients with anti-SAE DM in our case series presented with cutaneous involvement. • Atypical skin manifestations were present and included erythroderma, panniculitis, and hiker's feet.
Indexed as
Identifiers
40167943What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.